Research
Tesamorelin: what the evidence covers
Tesamorelin is one of the few compounds in this market with an FDA-approved product behind it. The approval covers a narrow problem in a specific group of patients, and that is usually not the reason it is being offered.
- The Tesamorelin board scores the sellers that publish a Tesamorelin price, on what each one discloses.
- Set against another compound on the same evidence standard: Sermorelin vs tesamorelin and Tesamorelin vs CJC-1295.
What tesamorelin is
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. It is a signal, not a hormone replacement. It acts on the pituitary gland and signals it to release the growth hormone the body already makes.
That places tesamorelin in the same family as sermorelin. The difference is a chemical modification added to the molecule, which makes it hold together longer in the body before enzymes break it down. The target and the pathway are the same.
Because the release still passes through the pituitary, it remains subject to the braking signals that normally limit growth hormone. This is the standard argument for the whole class, and for tesamorelin it is a fair description of the physiology.
The approval is real, and it is narrow
Tesamorelin has an approved US product, sold under the brand name Egrifta. It was approved to reduce excess abdominal fat in people with HIV who have lipodystrophy, a change in how the body stores fat that is associated with the infection and its treatment.
Read that indication carefully, because every word in it is load-bearing. The population is people living with HIV. The problem is a specific pattern of fat accumulation inside the abdomen, around the organs, rather than body weight in general. The approved labeling is explicit that this is not a weight-loss drug.
The trials that supported it measured that abdominal fat directly with imaging, in that population, against placebo. This is what a completed evidence package looks like, and tesamorelin has one. It is also the reason tesamorelin is a useful yardstick for the rest of the category.
Why the approval does not transfer to the wellness market
An approval answers one question about one group of people. Tesamorelin is now widely offered as a compounded preparation to adults who do not have HIV, for body composition, recovery and the general promise of aging more slowly. None of those uses were the question the trials asked.
Three things change at once when a drug moves outside its indication. The people are different, so the starting biology is different. The outcome is different, because visceral fat in lipodystrophy is not the same target as looking leaner or feeling stronger. And the length of the observation is different, because trials in a defined patient group run to a protocol while off-label use runs indefinitely.
This is not an argument that tesamorelin does nothing outside its indication. It is an argument that nobody has shown what it does there. Those are different statements, and clinics routinely blur them by citing the HIV trials as though the reader were in them.
The effect depends on continuing
One finding from the trial program deserves more attention than it gets in marketing. When treatment stopped, the abdominal fat that had been reduced came back.
That is a normal property of a drug that works by holding a hormone signal at a different level. It is not a defect. But it changes what a person is actually buying, because the result is rented rather than acquired.
It also changes how the price should be read. A compound that has to be continued for the effect to persist is an open-ended monthly cost, not a course with an end date.
What the label documents about tolerability
Because tesamorelin went through approval, there is a reviewed label describing what was seen in the trials. That is more than almost any other compound in this market has.
The effects reported in that work include injection site reactions, joint pain, swelling and fluid retention, and muscle aches. Growth hormone and insulin-like growth factor 1 both rise, which is the intended pharmacology, and the label carries cautions tied to that rise. Glucose handling is one of them. Use in people with active cancer is another, because the growth hormone axis is involved in cell growth.
None of this is a set of instructions. Whether any of it applies to a given person is a conversation with a prescriber who knows that person's history, working from the labeling that comes with the product.
Compounded tesamorelin is a different product from the approved one
Most tesamorelin sold through telehealth is compounded rather than dispensed as the branded product. A compounded preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality. That is a statement about the review pathway, not an accusation against any pharmacy.
The practical consequence is that the trial evidence and the vial can come apart. The evidence describes a product made to an approved specification and tested against it. A compounded version is a different article made by a different facility, and the approval does not extend to it.
Which substances may be compounded at all is governed by rules that are actively contested rather than settled for several peptides. How that resolves is not known, and no outcome is characterized here.
How we graded this, and what would change it
Tesamorelin is graded limited evidence. That grade is not a comment on the HIV lipodystrophy approval, which is genuinely strong for what it covers. It describes the gap between that approval and the uses the compound is actually sold for here.
What would move the grade is the same work that produced the approval, repeated for a different question. Randomized, placebo-controlled trials in adults who resemble the people buying it, measuring an outcome those people would notice, running long enough to show the effect holds.
Tesamorelin proves that bar is clearable for this class of molecule. It cleared it once, in a population that is not the one being marketed to now.
Key takeaways
- Tesamorelin is a growth-hormone-releasing hormone analogue, in the same class as sermorelin.
- It has a real FDA approval, for reducing excess abdominal fat in people with HIV who have lipodystrophy.
- The approved labeling states it is not a weight-loss drug.
- The trial program indicated the effect reverses when treatment stops.
- Almost all tesamorelin sold through telehealth is compounded and used outside that indication, where the trials have not been done.
Frequently asked questions
Is tesamorelin FDA-approved?
Yes, for one indication. An approved product is sold in the United States under the brand name Egrifta, for reducing excess abdominal fat in people with HIV who have lipodystrophy. That approval does not cover general fat loss, body composition in healthy adults, athletic recovery, or anti-aging use. Most tesamorelin sold through telehealth is a compounded preparation offered outside that indication, and a compounded product is not the approved one.
Is tesamorelin a weight-loss drug?
No. The approved labeling states that it is not indicated for weight loss. The trials behind the approval measured fat stored deep inside the abdomen, around the organs, in a specific patient group. That is a different target from body weight, and reducing it is not the same result as losing weight. Compounds that are approved for weight loss went through a separate and different set of trials.
How is tesamorelin different from sermorelin?
Both are analogues of growth-hormone-releasing hormone, and both work by signaling the pituitary to release the body's own growth hormone. Tesamorelin carries a chemical modification that makes it last longer before enzymes break it down. The larger practical difference is the evidence behind them. Tesamorelin completed the trials needed for an FDA approval in a defined population. Sermorelin has never had that work done for the adult wellness uses it is sold for.
Does the benefit last after stopping?
The trial program indicated that it does not. Abdominal fat returned after treatment stopped. This is expected for a drug that works by holding a hormone signal at a different level rather than by changing something permanently. It means the effect is tied to continued use, which is worth understanding before committing to an open-ended monthly cost.
Why is tesamorelin graded limited rather than strong?
Because the grade describes the evidence for how a compound is sold here, and tesamorelin is overwhelmingly sold outside its approved indication. For the HIV lipodystrophy use, the evidence is strong and the approval reflects that. For body composition in healthy adults, which is what the telehealth market offers it for, the controlled trials have not been done. The grade tracks the second situation, because that is the one a reader shopping for it is in.